Jul 15, 2026

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:

• Introduction (00:00)
• Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander...

Jul 14, 2026

Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics:

·      Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)

·      Case: A woman in her early 60s with multiregimen-recurrent...

Jul 13, 2026

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:

• Introduction: ODAC — April 30, 2026 (00:00)
• Adjuvant CDK4/6 Inhibitors (13:03)
• Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
• Premenopausal Patients (30:52)
• Duration of Adjuvant Endocrine...

Jul 13, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Localized HR-Positive Breast Cancer | Faculty Presentation 2: Genomic Evaluation for Treatment Decision-Making in Localized HR-Positive Breast Cancer — Joyce O’Shaughnessy, MD

CME information and select...

Jul 13, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Localized HR-Positive Breast Cancer | Faculty Presentation 1: Advances in the Use of Endocrine Therapy for Localized HR-Positive Breast Cancer — Harold J Burstein, MD, PhD

CME information and select...